查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010927

腦腫瘤治療市場：2026-2032年全球市場預測（依適應症、藥物類別、給藥途徑、最終用戶及通路分類）

Brain Cancer Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦腫瘤治療市場價值將達到 23.4 億美元，到 2026 年將成長至 25.1 億美元，到 2032 年將達到 39.3 億美元，複合年成長率為 7.66%。

主要市場統計數據
基準年 2025 23.4億美元
預計年份：2026年 25.1億美元
預測年份 2032 39.3億美元
複合年成長率 (%) 7.66%

本文概述了在科學和商業性快速變革的背景下，腦腫瘤治療的當前策略格局。

本文將腦腫瘤治療定位為腫瘤學領域的首要關注點，這主要源自於亟待滿足的迫切需求和加速發展的科學創新。臨床複雜性、血腦障壁挑戰、診斷異質性以及監管要求等因素共同導致轉化研究的成功需要分子生物學、遞送技術和臨床試驗設計等方面的綜合能力。近年來，腦腫瘤治療的手段不斷拓展，從細胞毒性藥物擴展到生物製藥、細胞療法以及旨在調節腫瘤微環境和免疫反應的標靶小分子化合物。

腦腫瘤治療的治療方法和商業模式將發生重大變革。

近年來，多項變革性變化改變了研發人員、臨床醫生和支付方對腦腫瘤治療的認知。精準腫瘤學已從概念走向實踐，分子譜分析能夠識別可治療的突變並指南患者選擇策略，從而改變了臨床試驗設計，並實現了主導生物標記的適應症。同時，免疫療法技術日益成熟，癌症疫苗、CAR-T療法和查核點抑制劑等療法正在中樞神經系統疾病的治療中進行測試。這些技術促使人們重新思考聯合治療以及適用於免疫機制的新型終點指標。

評估 2025 年美國關稅對腦腫瘤治療的供應鏈、定價和策略採購的累積影響。

關稅的實施為跨境供應鏈中的製藥企業、契約製造和經銷商帶來了新的考量。關稅的變化會改變從國際供應商採購的活性成分和輔料的相對成本結構，促使企業重新評估其供應商多元化、近岸外包和庫存策略。由於許多腦腫瘤治療依賴特殊的原料、生物成分或醫療設備相關的給藥系統，即使投入成本略有增加，也可能對生產計劃和合約定價結構產生連鎖反應。

透過按適應症、藥物類別、給藥途徑、最終用戶和分銷管道進行細分所獲得的見解，可以幫助制定策略重點。

基於適應症的細分揭示了臨床需求和研發重點的異質性。膠質母細胞瘤由於其高度侵襲性的生物學特性，仍存在未滿足的醫療需求；而腦膜瘤、轉移性腦瘤和腦下垂體瘤則各自需要不同的治療方法和監管途徑。了解這些臨床差異有助於明確標靶選擇和臨床試驗設計。基於藥物類別的細分錶明，化療仍然是某些治療方法的基礎支柱，其中烷化劑、抗代謝藥物和植物生物鹼發揮細胞毒性作用。同時，癌症疫苗、CAR-T療法和查核點抑制劑等免疫療法提供了免疫介導的策略，可以為特定患者群體帶來持續的療效。支持療法，例如止吐藥和生長因子，在維持劑量強度和保護患者的生活品質方面發揮至關重要的作用。標靶治療，包括單株抗體和蛋白酪氨酸激酶抑制劑，能夠精準標靶化致癌性驅動因子和訊號通路。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和競爭格局影響著市場進入和合作策略。

由於法律規範、報銷系統、臨床研究能力和醫療基礎設施的差異，區域趨勢差異顯著。在美洲，成熟的高品質醫療中心和強大的臨床試驗網路支持新療法的早期引入並促進患者快速入組，同時支付方也越來越重視真實世界療效證據。在歐洲、中東和非洲，監管協調和國家衛生技術評估流程的推進需要周密的市場准入規劃和長期的衛生經濟模型，以確保新療法能夠被納入處方藥目錄。在亞太地區，對癌症研究的快速投入、醫院容量的擴充以及本地生產能力的提升，為擴大規模提供了機遇，但也帶來了監管路徑和定價環境多樣性帶來的複雜性。

深入了解推動腦腫瘤治療進步的公司層面能力、策略定位和合作模式。

領先的製藥和生物技術公司正在多個領域加強自身能力，以保持腦腫瘤治療領域的成長動能。研發投入日益集中於增強中樞神經系統穿透性的平台、基於生物標記的患者篩選以及標靶治療與免疫調節劑聯合應用的策略。除了病毒載體和細胞療法等專業生產能力外，各公司還透過與診斷開發公司合作，共同開發伴隨診斷檢測，從而實現精準的患者招募和適應症區分，以此來提升自身競爭力。

為產業領導者提供切實可行的建議，以加強開發平臺、市場進入和以病人為中心的服務模式。

行業領導者應優先考慮與監管機構和保險公司進行早期且反覆的對話，以就證據要求和能夠反映切實臨床獲益的可接受終點達成一致。投資於伴隨診斷和標準化生物標記檢測將提高臨床實驗臨床實驗的效率，並支持針對特定適應症的索賠。從營運角度來看，提高供應鏈冗餘度並尋求區域性生產夥伴關係，可以在降低關稅和物流風險的同時，縮短臨床試驗週期。

本報告提供了透明的調查方法，解釋了資料來源、分析方法以及支持研究結果的檢驗過程。

本調查方法整合了第一手調查和第二手調查，以確保研究結果的全面性和有效性。第一手調查包括對臨床研究人員、腫瘤藥劑師、保險公司、醫院採購負責人和行業高管進行結構化訪談，並輔以諮詢委員會的諮詢，以了解臨床實踐模式和推廣應用障礙。第二手調查包括同行評審文獻、監管文件、臨床試驗註冊信息、會議論文集和公司資訊披露，以了解技術趨勢、作用機制的進展和監管先例。

全面概述腦腫瘤治療領域相關人員的臨床預期、商業性現實和策略挑戰。

總之，目前腦瘤治療的現況呈現出科學界對治療寄予厚望，但研發和商業化過程中卻面臨許多複雜挑戰的局面。精準醫療、免疫療法和遞送技術的進步拓展了有前景的治療策略範圍，但要將其廣泛應用於臨床實踐，需要在臨床開發、診斷、生產和醫保支付方合作等方面做出協調一致的努力。供應鏈壓力和關稅趨勢要求企業採取策略性採購策略，並考慮區域性生產。同時，不同地區監管環境和報銷機制的差異也要求企業採取個人化的市場進入策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腦腫瘤治療市場：依適應症分類

  • 多形性膠質母細胞瘤
  • 腦膜瘤
  • 轉移性腦瘤
  • 腦下垂體瘤

第9章：腦腫瘤治療市場：依藥物類別分類

  • 化療
    • 烷化劑
    • 抗代謝物
    • 植物生物鹼
  • 免疫療法
    • 癌症疫苗
    • CAR-T療法
    • 查核點抑制劑
  • 支持性護理
    • 止吐藥
    • 生長因子
  • 分子標靶治療
    • 單株抗體
    • 蛋白酪氨酸激酶抑制劑

第10章：腦腫瘤治療市場：依給藥途徑分類

  • 鞘內腔
  • 靜脈注射
  • 口服

第11章：腦腫瘤治療市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院

第12章：腦腫瘤治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：腦腫瘤治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：腦腫瘤治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腦腫瘤治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國腦腫瘤治療市場

第17章：中國腦腫瘤治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Arbor Pharmaceuticals, LLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation（a Bristol-Myers Squibb company）
  • DNAtrix, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Ipsen SA
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Kazia Therapeutics Limited
  • Merck KGaA
  • Mundipharma International Limited
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-434CCDA05263

The Brain Cancer Drugs Market was valued at USD 2.34 billion in 2025 and is projected to grow to USD 2.51 billion in 2026, with a CAGR of 7.66%, reaching USD 3.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.34 billion
Estimated Year [2026] USD 2.51 billion
Forecast Year [2032] USD 3.93 billion
CAGR (%) 7.66%

Framing the Current Strategic Context for Brain Cancer Therapeutics Amid Rapid Scientific and Commercial Change

The introduction positions brain cancer drugs as a high-priority area within oncology, driven by an urgent unmet medical need and accelerating scientific innovation. Clinical complexity, blood-brain barrier challenges, diagnostic heterogeneity, and regulatory expectations together create a landscape where translational success requires integrated capabilities across molecular biology, delivery technologies, and clinical trial design. Recent advances have expanded the therapeutic toolkit beyond cytotoxic agents to include biologics, cell therapies, and targeted small molecules that aim to modulate tumor microenvironments and immune responses.

From a commercial perspective, stakeholders must balance high development costs and protracted clinical pathways with the potential for durable clinical benefit in select patient populations. Payers and health technology assessment bodies are increasingly focused on real-world evidence and value-based contracting, which places a premium on post-approval evidence generation and adaptive reimbursement arrangements. Consequently, strategic planning now emphasizes diversified portfolios, earlier engagement with regulators and payers, and investment in companion diagnostics and novel delivery platforms to maximize the probability of clinical and commercial success.

Taken together, the introduction highlights the dual imperative: advancing cutting-edge science while pragmatically addressing commercialization, access, and delivery challenges to ensure that innovations translate into meaningful patient outcomes.

Major Transformative Shifts Redefining Treatment Approaches and Commercial Models Across Brain Cancer Therapeutics

Over recent years, several transformative shifts have altered how developers, clinicians, and payers approach brain cancer drugs. Precision oncology has moved from concept to practice as molecular profiling identifies actionable alterations and informs patient selection strategies, thereby changing clinical trial designs and enabling biomarker-driven indications. Concurrently, immunotherapeutic modalities have matured, with cancer vaccines, CAR-T approaches, and checkpoint inhibitors being tested in central nervous system indications; these modalities have prompted reconsideration of combination regimens and novel endpoints suited to immunologic mechanisms.

At the same time, targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, have adapted to constraints imposed by the blood-brain barrier through innovative formulation strategies and delivery tools, which include both systemic modifications and localized administration methods. Supportive therapies, such as anti-emetics and growth factors, have become integral to comprehensive patient management, improving tolerability and enabling sustained delivery of primary agents. The role of digital health, advanced imaging, and liquid biopsies has also expanded, enabling more dynamic monitoring of disease trajectory and therapy response. Collectively, these shifts demand new operational models, collaborative ecosystems with diagnostic partners, and an increased emphasis on post-market evidence generation to demonstrate long-term benefit and value.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Supply Chains, Pricing, and Strategic Sourcing in Brain Cancer Therapeutics

The imposition of tariffs has introduced new considerations for pharmaceutical manufacturers, contract manufacturers, and distributors that operate across transnational supply chains. Tariff changes can alter the relative cost structure of active pharmaceutical ingredients and excipients sourced from international suppliers, prompting firms to reassess supplier diversification, nearshoring, and stockpiling strategies. For brain cancer therapeutics-many of which rely on specialized raw materials, biologic components, or device-related delivery systems-any incremental input cost can cascade through manufacturing schedules and contractual pricing structures.

Moreover, tariffs have implications for clinical trial logistics and the movement of investigational medicinal products between study sites, potentially increasing administrative overhead and necessitating earlier contingency planning. Payers and procurement teams may respond to altered cost baselines by tightening formularies or emphasizing cost-effectiveness data, which underscores the importance of demonstrating differential clinical value. In response, industry players are pursuing strategies such as renegotiating supplier agreements, transferring select manufacturing steps to tariff-favored jurisdictions, and accelerating localization of critical inputs. Ultimately, the net effect is an increased premium on supply chain resilience and strategic sourcing decisions, with successful organizations prioritizing flexibility and transparent cost modeling to mitigate tariff-driven disruptions.

Insights Derived from Segmentation by Indication, Drug Class, Administration Route, End User, and Distribution Channel That Inform Strategic Priorities

Segmentation by indication clarifies heterogeneity in clinical need and development emphasis, with glioblastoma multiforme representing persistent unmet needs due to its aggressive biology, while meningioma, metastatic brain tumors, and pituitary tumors each require distinct therapeutic approaches and regulatory pathways. Understanding those clinical distinctions sharpens target selection and trial design. Segmentation by drug class highlights that chemotherapy remains a foundational backbone in some regimens, with alkylating agents, antimetabolites, and plant alkaloids delivering cytotoxic mechanisms. Meanwhile, immunotherapy modalities such as cancer vaccines, CAR-T therapy, and checkpoint inhibitors offer immune-mediated strategies that may provide durable responses in selected cohorts. Supportive therapy components like anti-emetics and growth factors play a critical role in maintaining dose intensity and patient quality of life. Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, enable precision targeting of oncogenic drivers and signaling pathways.

Route of administration segmentation-intrathecal, intravenous, and oral-drives considerations around formulation development, patient adherence, and facility requirements, and it informs decisions on outpatient versus inpatient delivery models. End user segmentation across clinics, home healthcare, and hospitals shapes operational planning for infusion capacity, home administration protocols, and training needs for multidisciplinary teams. Distribution channel segmentation differentiates hospital pharmacies, online pharmacies, and retail pharmacies, each presenting unique compliance, cold chain, and reimbursement touchpoints that influence market access strategies. By integrating these segment lenses, stakeholders can prioritize resource allocation, refine clinical development plans, and align commercialization approaches with the operational realities of delivery and access.

Regional Dynamics and Competitive Contexts Across the Americas, Europe, Middle East & Africa, and Asia-Pacific That Shape Market Entry and Partnership Strategies

Regional dynamics vary substantially, driven by differences in regulatory frameworks, reimbursement architectures, clinical research capacity, and healthcare infrastructure. In the Americas, established centers of excellence and robust clinical trial networks support early adoption of novel therapeutics and facilitate rapid patient accrual, while payers increasingly demand real-world outcome evidence. In Europe, Middle East & Africa, regulatory harmonization efforts and national health technology assessment processes require nuanced market access planning and long-term health economic modeling to secure formulary inclusion. In Asia-Pacific, rapid investments in oncology research, expanding hospital capacity, and growing local manufacturing capabilities present both scale opportunities and complexity related to heterogeneous regulatory pathways and pricing environments.

Across these regions, partnership models differ: collaborations with academic centers and contract research organizations support translational research in advanced markets, while alliances with regional distributors and local manufacturers enable market entry where localized production or regulatory familiarity is advantageous. Clinical adoption is influenced by variations in diagnostic capacity and standard-of-care practices, which can affect the pace of uptake for biomarker-driven therapies. Therefore, region-specific strategies that consider regulatory timing, reimbursement levers, and local clinical practice are essential for effective deployment of brain cancer therapeutics.

Key Company-Level Insights on Capabilities, Strategic Positioning, and Collaboration Models Driving Progress in Brain Cancer Therapeutics

Leading pharmaceutical and biotechnology companies are strengthening capabilities across several domains to sustain momentum in brain cancer therapeutics. R&D investments are increasingly concentrated on platforms that enhance central nervous system penetration, biomarker-driven patient selection, and combination strategies that pair targeted agents with immune modulators. Companies are differentiating through specialized manufacturing competencies, including viral vector and cell therapy production, as well as through strategic partnerships with diagnostic developers to co-develop companion assays that enable precise enrollment and label differentiation.

Collaboration models show a clear trend toward risk-sharing alliances between innovators, contract manufacturing organizations, academic centers, and biotechnology partners. These models facilitate access to niche expertise, accelerate early-phase development, and de-risk later-stage programs. Portfolio strategies favor a balance between novel mechanisms of action and assets that enhance tolerability or extend durability of response. Additionally, business development activity increasingly emphasizes in-licensing of promising early-stage assets and targeted acquisitions that complement delivery technologies or diagnostic capabilities. Overall, successful organizations demonstrate integrated clinical, regulatory, and commercial planning supported by strategic external partnerships.

Actionable Recommendations for Industry Leaders to Strengthen Development Pipelines, Market Access, and Patient-Centered Delivery Models

Industry leaders should prioritize early and iterative engagement with regulatory agencies and payers to align on evidence requirements and acceptable end points that reflect meaningful clinical benefit. Investing in companion diagnostics and standardized biomarker assays will improve trial efficiency and support targeted labeling claims. From an operational perspective, enhancing supply chain redundancy and pursuing regional manufacturing partnerships can mitigate tariff and logistic risks while shortening time-to-clinic for investigational products.

Companies should also design development programs that build robust real-world evidence pathways, including registries and post-approval studies, to support durable reimbursement agreements. Emphasizing tolerability and quality-of-life outcomes alongside efficacy will aid in demonstrating value to clinicians and payers. Collaboration with home healthcare providers and hospitals to develop safe administration protocols will expand access and reduce treatment burden for patients. Finally, adopting flexible commercial models-such as outcome-linked contracting and tailored regional pricing strategies-can facilitate access across diverse healthcare systems while protecting commercial sustainability.

Transparent Research Methodology Explaining Data Sources, Analytic Approaches, and Validation Processes That Underpin the Report's Findings

The research methodology integrates primary and secondary approaches to ensure comprehensive coverage and validation of insights. Primary research comprises structured interviews with clinical investigators, oncology pharmacists, payers, hospital procurement officers, and industry executives, supplemented by advisory board consultations to contextualize practice patterns and adoption barriers. Secondary research includes peer-reviewed literature, regulatory documents, clinical trial registries, conference proceedings, and company disclosures to map technological trends, mechanism of action developments, and regulatory precedents.

Analytical techniques include qualitative thematic analysis to synthesize stakeholder perspectives and quantitative cross-sectional analyses to examine adoption patterns across segments and regions. Triangulation of data sources and iterative validation with subject-matter experts are employed to reduce bias and confirm findings. The methodology acknowledges limitations related to the evolving clinical landscape and potential lag between emerging scientific developments and peer-reviewed evidence, and it emphasizes that conclusions are intended to inform strategic decision-making rather than provide prescriptive clinical guidance.

Concluding Synthesis That Integrates Clinical Promise, Commercial Realities, and Strategic Imperatives for Brain Cancer Drug Stakeholders

In conclusion, the brain cancer therapeutics landscape is characterized by significant scientific promise alongside complex developmental and commercialization challenges. Advances in precision medicine, immunotherapy, and delivery science have expanded the array of plausible therapeutic strategies, but successful translation into widespread clinical practice requires coordinated efforts across clinical development, diagnostics, manufacturing, and payer engagement. Supply chain pressures and tariff dynamics have added urgency to strategic sourcing and regional manufacturing considerations, while regional heterogeneity in regulatory and reimbursement systems demands tailored market access approaches.

To capitalize on emerging opportunities, organizations must combine scientific rigor with pragmatic commercial planning: design biomarker-enabled trials, invest in companion diagnostics and real-world evidence, strengthen manufacturing and distribution resilience, and pursue collaborative alliances that bring complementary capabilities. By aligning clinical innovation with operational excellence and payer-focused evidence generation, stakeholders can improve patient access to meaningful treatments and create sustainable value across the therapeutic ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Cancer Drugs Market, by Indication

  • 8.1. Glioblastoma Multiforme
  • 8.2. Meningioma
  • 8.3. Metastatic Brain Tumors
  • 8.4. Pituitary Tumors

9. Brain Cancer Drugs Market, by Drug Class

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Antimetabolites
    • 9.1.3. Plant Alkaloids
  • 9.2. Immunotherapy
    • 9.2.1. Cancer Vaccines
    • 9.2.2. CAR-T Therapy
    • 9.2.3. Checkpoint Inhibitors
  • 9.3. Supportive Therapy
    • 9.3.1. Anti-Emetics
    • 9.3.2. Growth Factors
  • 9.4. Targeted Therapy
    • 9.4.1. Monoclonal Antibodies
    • 9.4.2. Tyrosine Kinase Inhibitors

10. Brain Cancer Drugs Market, by Route Of Administration

  • 10.1. Intrathecal
  • 10.2. Intravenous
  • 10.3. Oral

11. Brain Cancer Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Brain Cancer Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Brain Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Brain Cancer Drugs Market

17. China Brain Cancer Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. Arbor Pharmaceuticals, LLC
  • 18.8. AstraZeneca PLC
  • 18.9. Bayer AG
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Celgene Corporation (a Bristol-Myers Squibb company)
  • 18.12. DNAtrix, Inc.
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. Ipsen SA
  • 18.16. Johnson & Johnson
  • 18.17. Karyopharm Therapeutics Inc.
  • 18.18. Kazia Therapeutics Limited
  • 18.19. Merck KGaA
  • 18.20. Mundipharma International Limited
  • 18.21. Novartis AG
  • 18.22. Novocure GmbH
  • 18.23. Pfizer Inc.
  • 18.24. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. G7 BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. G7 BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. NATO BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. NATO BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. NATO BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)